Schedule 13G ownership disclosure

Sutro Biopharma, Inc.

Common Stock, $0.001 par value · CUSIP: 869367201

Event date: 2026-02-10

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L P

    Shares: 668,693.00 · Class: 4.1%

  • BVF I GP LLC

    Shares: 668,693.00 · Class: 4.1%

  • BIOTECHNOLOGY VALUE FUND II LP

    Shares: 488,916.00 · Class: 3.0%

  • BVF II GP LLC

    Shares: 488,916.00 · Class: 3.0%

  • Biotechnology Value Trading Fund OS LP

    Shares: 75,359.00 · Class: 0.5%

  • BVF Partners OS Ltd.

    Shares: 75,359.00 · Class: 0.5%

  • BVF GP HOLDINGS LLC

    Shares: 1,157,609.00 · Class: 7.0%

  • BVF PARTNERS L P/IL

    Shares: 1,251,788.00 · Class: 7.6%

  • BVF INC/IL

    Shares: 1,251,788.00 · Class: 7.6%

  • LAMPERT MARK N

    Shares: 1,251,788.00 · Class: 7.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-26-000502
Form type
SCHEDULE 13G
Filer
BIOTECHNOLOGY VALUE FUND L P
CIK
CIK 918923
Filed
Feb 18, 2026
Reporting period
Feb 10, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub